Table 5. Planned or ongoing NIRS studies.
| Study | Question | Patients | Design | Reference number |
|---|---|---|---|---|
| PROSPECT 2 | Does NIRS/IVUS predict coronary events | 900 | Prospective study analyzing angiographic information from patients with ACS | NCT02171065 |
| PROSPECT ABSORB | Does ABSORB BVS improve MLA in non-flow limiting plaque with a plaque burden >65% | 300 | RCT-sealing of non-flow limiting high risk plaques with BVS | NCT02171065 |
| LRP | NIRS detected LRP and prediction of future events | 6,000 | Event rate in large vs. small or no LRP | NCT02033694 |
| YELLOW 2 | Does rosuvastatin reduce lipid content of plaques | 80 | Angiography and NIRS after 8−10 weeks of rosuvastatin treatment compared to atorvastatin | NCT01837823 |
| ORACLE-NIRS | Incidence of major adverse events in patients examined with NIRS for clinical events | 10,000 | Registry data | NCT02265146 |
| NIRS TICAGRELOR | Does ticagrelor reduce lipid rich plaques | 30 | NIRS and IVUS before and after 6 months of ticagrelor | NCT02282332 |
NIRS, near infra-red spectroscopy; IVUS, intravascular ultrasound; BVS, bioresorbable vascular scaffold; MLA, minimal lumen diameter; LRP, lipid rich plaque; ACS, acute coronary syndrome. Modified from Erlinge et al. (67).